-+ 0.00%
-+ 0.00%
-+ 0.00%

Evogene Partners With Research Group Of Dr. Mark Adams Over Discovery, Optimization Of Small Molecules To Treat Chemotherapy, Targeted Therapy-Resistant Non-small Cell Lung Cancer

Benzinga·02/17/2026 13:05:11
Listen to the news

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for the treatment of chemotherapy and targeted therapy-resistant non-small cell lung cancer (NSCLC), as well as other cancers.